Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Adtalem Global Education  / Technical Analysis

<ul>
<li>As discussed throughout January, we believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared.</li>
<li>We reiterated this in yesterday's pre-market ETF Pathfinder (Feb.3), also noting "we anticipate the Canada/Mexico tariffs to be resolved quickly, and we view the latest pullback as a buying opportunity."</li>
<li>Sure enough, both Mexico and, later, Canada, came to an agreement with Trump to delay tariffs for 30 days. Short-term support remains at the prior 1-month downtrend on the SPX.</li>
</ul>


As discussed throughout January, we believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared.
We reiterated this in yesterday's pre-market ETF Pathfinder (Feb.3), also noting "we anticipate the Canada/Mexico tariffs to be resolved quickly, and we view the latest pullback as a buying opportunity."
Sure enough, both Mexico and, later, Canada, came to an agreement with Trump to delay tariffs for 30 days. Short-term support remains at the prior 1-month downtrend on the SPX.


S&P 500 Holding Above Prior Breakout Level Yet Again; Market Dynamics Remain Risk-On; Still Bullish

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Fresenius Medical Care  &  / Equity Bottom-Up

<ul><li>Fresenius Medical Care, a global leader in dialysis care, presented its second quarter 2024 earnings with a mix of continued strategic progress and facing external challenges.</li><li>During the earnings call, CEO, Helen Giza, outlined the efforts and achievements in line with the company's transformation and long-term strategic plans.</li><li>The focus was notably on driving better financial performance and moving toward the 2025 group margin targets.</li></ul>

Fresenius Medical Care, a global leader in dialysis care, presented its second quarter 2024 earnings with a mix of continued strategic progress and facing external challenges.During the earnings call, CEO, Helen Giza, outlined the efforts and achievements in line with the company's transformation and long-term strategic plans.The focus was notably on driving better financial performance and moving toward the 2025 group margin targets.

Fresenius Medical Care:  A Deep Dive Of Its Business Strategy

<ul><li>Fresenius Medical Care, in its recent financial results, highlighted its commitment to continuing transformation and improvement across its segments.</li><li>Initiatives to streamline organizational structures, enhance clinic utilization, and advance strategic growth areas, notably in value-based care, were emphasized.</li><li>The company's focus on optimizing manufacturing and supply chain processes is a critical element in its strategy to achieve margin improvements by 2025.</li></ul>

Fresenius Medical Care, in its recent financial results, highlighted its commitment to continuing transformation and improvement across its segments.Initiatives to streamline organizational structures, enhance clinic utilization, and advance strategic growth areas, notably in value-based care, were emphasized.The company's focus on optimizing manufacturing and supply chain processes is a critical element in its strategy to achieve margin improvements by 2025.

Fresenius Medical Care AG & Co.: How Are They Executing Portfolio Optimization through Divestitures? - Major Growth Drivers

<ul><li>Fresenius Medical Care's Q4 2023 earnings highlighted the progress made against their strategic plan that was set out a year prior.</li><li>The plan focused on significant structural, operational and cultural changes, with the operating model being transformed at the start of 2023.</li><li>This allowed the company to introduce a new financial report with increased transparency, which reflected a commitment to their operational turnaround initiatives that aided organic growth in both segments and improved operational performance.</li></ul>

Fresenius Medical Care's Q4 2023 earnings highlighted the progress made against their strategic plan that was set out a year prior.The plan focused on significant structural, operational and cultural changes, with the operating model being transformed at the start of 2023.This allowed the company to introduce a new financial report with increased transparency, which reflected a commitment to their operational turnaround initiatives that aided organic growth in both segments and improved operational performance.

Fresenius Medical Care: Initiation Of Coverage - Innovation with AR in Dialysis Training & 4 Other Major Drivers

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The potential/market size of GLP-1 drugs is much greater-than-expected. Indication expansion could easily generate big returns. Investment strategy for GLP-1 drugs should be long-term, which is expected to bring alpha.</li>
<li>Supply-Demand relationship of entire market would change due to popularization of GLP-1 drugs.This is not only for healthcare, but also cause a change in the investment logic of other industries.</li>
<li>It’s recommended to re-examine stock positions in portfolio. Because each indication expansion of GLP-1 drugs would mean a decrease in demand in another field, leading to potential stock price plummet.</li>
</ul>


The potential/market size of GLP-1 drugs is much greater-than-expected. Indication expansion could easily generate big returns. Investment strategy for GLP-1 drugs should be long-term, which is expected to bring alpha.
Supply-Demand relationship of entire market would change due to popularization of GLP-1 drugs.This is not only for healthcare, but also cause a change in the investment logic of other industries.
It’s recommended to re-examine stock positions in portfolio. Because each indication expansion of GLP-1 drugs would mean a decrease in demand in another field, leading to potential stock price plummet.


GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

Germany

Fresenius Medical Care AG & Co. KGaA offers kidney dialysis services and manufactures and distributes equipment and products used in the treatment of dialysis patients. The Company also offers clinical laboratory testing and diagnostic testing services and provides home infusion, respiratory therapy, ultrasound, and echo-cardiography. Fresenius operates worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fresenius Medical Care & (FMS US)

S&P 500 Holding Above Prior Breakout Level Yet Again; Market Dynamics Remain Risk-On; Still Bullish

S&P 500 $SPX Holding Above Prior Breakout Level Yet Again, as are most indexes $QQQ $ARKK $IJH $DJI $RSP; Market Dynamics Remain Risk-On; Bullish...

Vermilion Research

Fresenius Medical Care: A Deep Dive Of Its Business Strategy

Fresenius Medical Care, a global leader in dialysis care, presented its second quarter 2024 earnings with a mix of continued strategic progress...

Baptista Research

Fresenius Medical Care AG & Co.: How Are They Executing Portfolio Optimization through Divestitures? - Major Growth Drivers

Fresenius Medical Care, in its recent financial results, highlighted its commitment to continuing transformation and improvement across its...

Baptista Research

Fresenius Medical Care: Initiation Of Coverage - Innovation with AR in Dialysis Training & 4 Other Major Drivers

Fresenius Medical Care's Q4 2023 earnings highlighted the progress made against their strategic plan that was set out a year prior. The plan...

Baptista Research

GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

GLP-1s will be the next major opportunity in healthcare, which won't be limited to weight loss drugs. But when they expand new indications,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)